172 related articles for article (PubMed ID: 24528602)
1. Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.
Weidensteiner C; Allegrini PR; Sticker-Jantscheff M; Romanet V; Ferretti S; McSheehy PM
BMC Cancer; 2014 Feb; 14():88. PubMed ID: 24528602
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging of human melanoma xenografts in vivo: proton spin-lattice and spin-spin relaxation times versus fractional tumour water content and fraction of necrotic tumour tissue.
Rofstad EK; Steinsland E; Kaalhus O; Chang YB; Høvik B; Lyng H
Int J Radiat Biol; 1994 Mar; 65(3):387-401. PubMed ID: 7908318
[TBL] [Abstract][Full Text] [Related]
3. Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability.
McSheehy PM; Weidensteiner C; Cannet C; Ferretti S; Laurent D; Ruetz S; Stumm M; Allegrini PR
Clin Cancer Res; 2010 Jan; 16(1):212-25. PubMed ID: 20008843
[TBL] [Abstract][Full Text] [Related]
4. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.
Cejka D; Preusser M; Woehrer A; Sieghart W; Strommer S; Werzowa J; Fuereder T; Wacheck V
Cancer Biol Ther; 2008 Sep; 7(9):1377-85. PubMed ID: 18708754
[TBL] [Abstract][Full Text] [Related]
5. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
O'Reilly T; Lane HA; Wood JM; Schnell C; Littlewood-Evans A; Brueggen J; McSheehy PM
Cancer Chemother Pharmacol; 2011 Jan; 67(1):193-200. PubMed ID: 20512579
[TBL] [Abstract][Full Text] [Related]
6. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.
Ferretti S; Allegrini PR; O'Reilly T; Schnell C; Stumm M; Wartmann M; Wood J; McSheehy PM
Clin Cancer Res; 2005 Nov; 11(21):7773-84. PubMed ID: 16278399
[TBL] [Abstract][Full Text] [Related]
7. FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo.
Cejka D; Kuntner C; Preusser M; Fritzer-Szekeres M; Fueger BJ; Strommer S; Werzowa J; Fuereder T; Wanek T; Zsebedics M; Mueller M; Langer O; Wacheck V
Br J Cancer; 2009 Jun; 100(11):1739-45. PubMed ID: 19436299
[TBL] [Abstract][Full Text] [Related]
8. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
[TBL] [Abstract][Full Text] [Related]
9. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma.
Chaumeil MM; Ozawa T; Park I; Scott K; James CD; Nelson SJ; Ronen SM
Neuroimage; 2012 Jan; 59(1):193-201. PubMed ID: 21807103
[TBL] [Abstract][Full Text] [Related]
10. Treatment with
Zari A; Alfarteesh H; Buckner C; Lafrenie R
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670520
[No Abstract] [Full Text] [Related]
11. Detection of necrosis in human tumour xenografts by proton magnetic resonance imaging.
Jakobsen I; Kaalhus O; Lyng H; Rofstad EK
Br J Cancer; 1995 Mar; 71(3):456-61. PubMed ID: 7880724
[TBL] [Abstract][Full Text] [Related]
12. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.
Papaevangelou E; Almeida GS; Jamin Y; Robinson SP; deSouza NM
Br J Cancer; 2015 Apr; 112(9):1471-9. PubMed ID: 25880014
[TBL] [Abstract][Full Text] [Related]
14. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
Hirashima K; Baba Y; Watanabe M; Karashima RI; Sato N; Imamura Y; Nagai Y; Hayashi N; Iyama KI; Baba H
Br J Cancer; 2012 Feb; 106(5):876-82. PubMed ID: 22333597
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.
Zhu Y; Zhang X; Liu Y; Zhang S; Liu J; Ma Y; Zhang J
Tumour Biol; 2012 Oct; 33(5):1349-62. PubMed ID: 22492237
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.
Canese R; Pisanu ME; Mezzanzanica D; Ricci A; Paris L; Bagnoli M; Valeri B; Spada M; Venditti M; Cesolini A; Rodomonte A; Giannini M; Canevari S; Podo F; Iorio E
NMR Biomed; 2012 Apr; 25(4):632-42. PubMed ID: 22020805
[TBL] [Abstract][Full Text] [Related]
17. Multimodal assessment of early tumor response to chemotherapy: comparison between diffusion-weighted MRI, 1H-MR spectroscopy of choline and USPIO particles targeted at cell death.
Radermacher KA; Magat J; Bouzin C; Laurent S; Dresselaers T; Himmelreich U; Boutry S; Mahieu I; Vander Elst L; Feron O; Muller RN; Jordan BF; Gallez B
NMR Biomed; 2012 Apr; 25(4):514-22. PubMed ID: 21874657
[TBL] [Abstract][Full Text] [Related]
18. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
[TBL] [Abstract][Full Text] [Related]
19. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
[TBL] [Abstract][Full Text] [Related]
20. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
